Tumor Associated Fibroblasts on Tumor Immune Response
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 199
Special Issue Editors
Interests: cancer stem-like cell; metastasis; breast cancer
2. Department of Human Anatomy and Embryology, University of Granada, Granada, Spain
3. Biosanitary Research Institute of Granada (ibs.GRANADA), Granada, Spain
Interests: biofabrication; organ on a chip; tissue engineering; cancer; regenerative medicine
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Tumors are not only composed of cancer cells, but also include a heterogenous collection of infiltrating and resident host cells, secreted factors and the extracellular matrix. This cellular and molecular complex forms the tumor microenvironment (TME). Crosstalk between the TME and cancer cells is a key driver of tumor initiation, progression, and metastasis. TME composition varies between tumor types, however, immune cells, stromal cells, blood vessels and the extracellular matrix are essential components for all solid cancer types. Among them, cancer-associated fibroblasts (CAFs) are the most abundant non-cancer cell types in the tumor microenvironment. It is known that early in tumor growth, a dynamic and reciprocal relationship develops between CAFs and cancer cells to support tumor growth and progression. One of the mechanisms by which CAFs promote cancer progression is by modulating the anti-tumor immune response. In this Special Issue, we aim to present recent findings on how CAFs can influence the tumor immune response through direct and indirect interaction with immune cells and other key components of the TME.
Dr. Manuel Picon-Ruiz
Dr. Juan Antonio Marchal Corrales
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
